Kazia receives a $2 million development milestone after Sovargen doses the first patient in a Phase 1b/2a paxalisib trial for rare seizure disorders. The event also leaves Kazia eligible for up to $17 million in further development and regulatory milestones, plus sublicensing Revenue and royalties on net sales.
Key Highlights
- The Phase 1b/2a study evaluates paxalisib in epilepsy associated with FCD T2 and TSC.
- Kazia and Sovargen entered their exclusive licensing agreement in March 2024.
- The Sovargen trial reached its first-patient milestone.
- The study is evaluating paxalisib in adults with FCD T2, TSC and hemimegalencephaly.
Sovargen Trial Reaches First-Patient Milestone
KAZIA Therapeutics Limited (NASDAQ: KZIA) is a biotechnology company. The study is assessing paxalisib in patients with intractable epilepsy linked to FCD T2 and TSC. The agreement covers all countries worldwide except mainland China, Hong Kong, Macao and Taiwan. Kazia and Sovargen entered the licensing arrangement in March 2024. FCD T2 and TSC are described as rare, genetically driven neurological disorders involving overactivation of the mTOR pathway and treatment-resistant seizures.
Further Milestones Remain Available
Kazia is eligible for up to $17 million in further development and regulatory milestone payments under the agreement. The arrangement also provides for a percentage of sublicensing revenue and royalties on net sales of products containing paxalisib. The companies said the clinical study will generate data as the program progresses. The release also identifies the trial as a Phase 1b/2a evaluation in adults with FCD T2, TSC and hemimegalencephaly.
FAQs
Q: What further payments can Kazia receive under the paxalisib licence?
A: Kazia may receive up to $17 million in later development and regulatory milestones. The agreement also includes sublicensing revenue and royalties on net sales.
Q: What is the Sovargen study assessing?
A: The study is assessing paxalisib in patients with intractable epilepsy linked to FCD T2 and TSC. It is identified as a Phase 1b/2a evaluation.
Q: When did Kazia and Sovargen enter their licensing arrangement?
A: Kazia and Sovargen entered the licensing arrangement in March 2024. The agreement covers worldwide countries except mainland China, Hong Kong, Macao and Taiwan.
Q: How much in further milestone payments may Kazia receive?
A: Kazia is eligible for up to $17 million in further development and regulatory milestone payments. The arrangement also includes a percentage of sublicensing revenue and royalties on net sales.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.